Welcome to our dedicated page for enGene Therapeutics SEC filings (Ticker: ENGNW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on enGene Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into enGene Therapeutics's regulatory disclosures and financial reporting.
enGene Therapeutics Inc. filed an amended report updating details of its previously announced strategic restructuring, which includes reducing its workforce by about 50% to streamline operations and preserve cash. The company now expects restructuring cash costs of approximately $5.7–$6.4 million and non-cash stock-based compensation of about $4.7–$5.0 million, mainly from accelerated option vesting.
enGene also estimates up to $1.7 million in cash retention costs and up to $2.8 million in non-cash stock-based compensation tied to new performance-based equity retention awards. These awards, including a 400,000-share option grant to CEO Ronald Cooper at $1.75 per share, vest only if FDA milestones for detalimogene are met by late 2027 and 2028.
enGene Therapeutics Inc. filed an amended report updating details of its previously announced strategic restructuring, which includes reducing its workforce by about 50% to streamline operations and preserve cash. The company now expects restructuring cash costs of approximately $5.7–$6.4 million and non-cash stock-based compensation of about $4.7–$5.0 million, mainly from accelerated option vesting.
enGene also estimates up to $1.7 million in cash retention costs and up to $2.8 million in non-cash stock-based compensation tied to new performance-based equity retention awards. These awards, including a 400,000-share option grant to CEO Ronald Cooper at $1.75 per share, vest only if FDA milestones for detalimogene are met by late 2027 and 2028.
enGene Therapeutics Inc. director Philip Astley-Sparke received a grant of stock options to acquire 31,000 common shares. The options have an exercise price of $1.75 per share and now represent a total option holding of 31,000 shares.
The option vests fully on the earlier of the first anniversary of the vesting commencement date, which was June 9, 2026, or the company’s 2027 annual meeting of shareholders. The options are scheduled to expire on June 16, 2036, if not exercised earlier.
enGene Therapeutics Inc. director Philip Astley-Sparke received a grant of stock options to acquire 31,000 common shares. The options have an exercise price of $1.75 per share and now represent a total option holding of 31,000 shares.
The option vests fully on the earlier of the first anniversary of the vesting commencement date, which was June 9, 2026, or the company’s 2027 annual meeting of shareholders. The options are scheduled to expire on June 16, 2036, if not exercised earlier.
enGene Therapeutics Inc. director Gerald A. Brunk received a grant of stock options covering 31,000 common shares. The options have an exercise price of $1.75 per share and were awarded at no cost.
The options expire on June 16, 2036. According to the disclosure, the option vests fully on the earlier of the first anniversary of the June 9, 2026 vesting commencement date or the company’s 2027 annual meeting of shareholders. Following this grant, Brunk holds options for 31,000 shares directly.
enGene Therapeutics Inc. director Gerald A. Brunk received a grant of stock options covering 31,000 common shares. The options have an exercise price of $1.75 per share and were awarded at no cost.
The options expire on June 16, 2036. According to the disclosure, the option vests fully on the earlier of the first anniversary of the June 9, 2026 vesting commencement date or the company’s 2027 annual meeting of shareholders. Following this grant, Brunk holds options for 31,000 shares directly.
enGene Therapeutics Inc. director Richard M. Glickman received a grant of stock options covering 31,000 common shares. The options have an exercise price of $1.75 per share and expire on June 16, 2036. Following this grant, he holds 31,000 options directly.
The option award vests fully on the earlier of the first anniversary of the vesting commencement date, which was June 9, 2026, or the company’s 2027 annual meeting of shareholders. This is a compensation-related award rather than an open-market purchase or sale.
enGene Therapeutics Inc. director Richard M. Glickman received a grant of stock options covering 31,000 common shares. The options have an exercise price of $1.75 per share and expire on June 16, 2036. Following this grant, he holds 31,000 options directly.
The option award vests fully on the earlier of the first anniversary of the vesting commencement date, which was June 9, 2026, or the company’s 2027 annual meeting of shareholders. This is a compensation-related award rather than an open-market purchase or sale.
enGene Therapeutics Inc. director and Interim Chief Medical Officer William Grossman reported receiving two stock option awards. He was granted options covering 200,000 common shares at an exercise price of $1.75 per share, vesting fully on the earlier of the first anniversary of a June 9, 2026 vesting commencement date or the company’s 2027 annual shareholder meeting, for his service as a non-executive director.
He was also granted options on 31,000 common shares at an exercise price of $1.75 per share, vesting in substantially equal monthly installments over 12 months, subject to his continued service as Interim Chief Medical Officer. Both awards expire on June 16, 2036 and are compensation grants rather than open-market purchases or sales.
enGene Therapeutics Inc. director and Interim Chief Medical Officer William Grossman reported receiving two stock option awards. He was granted options covering 200,000 common shares at an exercise price of $1.75 per share, vesting fully on the earlier of the first anniversary of a June 9, 2026 vesting commencement date or the company’s 2027 annual shareholder meeting, for his service as a non-executive director.
He was also granted options on 31,000 common shares at an exercise price of $1.75 per share, vesting in substantially equal monthly installments over 12 months, subject to his continued service as Interim Chief Medical Officer. Both awards expire on June 16, 2036 and are compensation grants rather than open-market purchases or sales.
enGene Therapeutics Inc. director Paul J. Hastings received a grant of stock options for 31,000 common shares. The options have an exercise price of $1.75 per share and expire on June 16, 2036. They vest in full on the earlier of the first anniversary of the June 9, 2026 vesting commencement date or the company’s 2027 annual meeting of shareholders.
enGene Therapeutics Inc. director Paul J. Hastings received a grant of stock options for 31,000 common shares. The options have an exercise price of $1.75 per share and expire on June 16, 2036. They vest in full on the earlier of the first anniversary of the June 9, 2026 vesting commencement date or the company’s 2027 annual meeting of shareholders.
enGene Therapeutics Inc. director Michael Thomas Heffernan reported receiving a stock option grant covering 31,000 Common Shares. The option has an exercise price of $1.75 per share, giving him the right to buy shares at that price in the future.
The option was granted as a compensation award and expires on June 16, 2036. It vests fully on the earlier of the first anniversary of the vesting commencement date, which was June 9, 2026, or the company’s 2027 annual meeting of shareholders.
enGene Therapeutics Inc. director Michael Thomas Heffernan reported receiving a stock option grant covering 31,000 Common Shares. The option has an exercise price of $1.75 per share, giving him the right to buy shares at that price in the future.
The option was granted as a compensation award and expires on June 16, 2036. It vests fully on the earlier of the first anniversary of the vesting commencement date, which was June 9, 2026, or the company’s 2027 annual meeting of shareholders.
enGene Therapeutics Inc. director Wouter Joustra received a grant of stock options covering 31,000 common shares. The options have an exercise price of $1.75 per share and expire on June 16, 2036. According to the footnote, the option vests fully on the earlier of the first anniversary of the vesting commencement date, which was June 9, 2026, or the company’s 2027 annual meeting of shareholders.
enGene Therapeutics Inc. director Wouter Joustra received a grant of stock options covering 31,000 common shares. The options have an exercise price of $1.75 per share and expire on June 16, 2036. According to the footnote, the option vests fully on the earlier of the first anniversary of the vesting commencement date, which was June 9, 2026, or the company’s 2027 annual meeting of shareholders.
enGene Therapeutics Inc. director Lota S. Zoth reported receiving a grant of stock options covering 31,000 common shares. The options have an exercise price of $1.75 per share and were awarded at no cost.
According to the terms, the entire option award vests on the earlier of the first anniversary of the vesting commencement date of June 9, 2026 or the company’s 2027 annual meeting of shareholders. After this grant, Zoth holds 31,000 stock options directly.
enGene Therapeutics Inc. director Lota S. Zoth reported receiving a grant of stock options covering 31,000 common shares. The options have an exercise price of $1.75 per share and were awarded at no cost.
According to the terms, the entire option award vests on the earlier of the first anniversary of the vesting commencement date of June 9, 2026 or the company’s 2027 annual meeting of shareholders. After this grant, Zoth holds 31,000 stock options directly.
enGene Therapeutics reported a net loss of $30.2M for the quarter and $60.0M for the six months ended April 30, 2026, driven by research and development and growing general and administrative costs. Operating cash outflow was $59.4M over six months.
The company held $29.8M in cash and cash equivalents and $255.2M in marketable securities, with total assets of $307.5M and shareholders’ equity of $255.2M. Management expects this liquidity to fund operations and debt obligations for at least 12 months, but anticipates needing additional capital thereafter.
enGene expanded its debt facility to up to $125M, drawing $25M, and raised equity through a late-2025 public offering and pre-funded warrants. Subsequent to quarter-end, it announced a workforce reduction of about 50% and a strategic restructuring to preserve cash while advancing its LEGEND trial of detalimogene and preparing for a potential BLA filing.
enGene Therapeutics reported a net loss of $30.2M for the quarter and $60.0M for the six months ended April 30, 2026, driven by research and development and growing general and administrative costs. Operating cash outflow was $59.4M over six months.
The company held $29.8M in cash and cash equivalents and $255.2M in marketable securities, with total assets of $307.5M and shareholders’ equity of $255.2M. Management expects this liquidity to fund operations and debt obligations for at least 12 months, but anticipates needing additional capital thereafter.
enGene expanded its debt facility to up to $125M, drawing $25M, and raised equity through a late-2025 public offering and pre-funded warrants. Subsequent to quarter-end, it announced a workforce reduction of about 50% and a strategic restructuring to preserve cash while advancing its LEGEND trial of detalimogene and preparing for a potential BLA filing.